Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Henan Zhongda Hengyuan Biotechnology Stock Co. Ltd. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 examiners and 1 art unit, indicating distinct examiner relationships within a common broader technical assignment.
EPSTEIN, TODD MATTHEW is the busiest examiner, with 1 pending matter. Counsel can coordinate the docket through the shared art-unit context while tailoring each response to its assigned examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PAK, YONG D | 1 | 74.7% | +14.2% |
| EPSTEIN, TODD MATTHEW | 1 | 60.8% | +43.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19041885 | COMPOSITE ENGINEERED BACTERIA AND METHOD FOR PRODUCING D-PSICOSE | PAK, YONG D | — |
| 19041945 | ENZYME COMBINATION, GENETICALLY ENGINEERED BACTERIA, AND APPLICATION THEREOF IN PRODUCING D-PSICOSE | EPSTEIN, TODD MATTHEW | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19041885 | COMPOSITE ENGINEERED BACTERIA AND METHOD FOR PRODUCING D-PSICOSE | PAK, YONG D | — |
| 19041945 | ENZYME COMBINATION, GENETICALLY ENGINEERED BACTERIA, AND APPLICATION THEREOF IN PRODUCING D-PSICOSE | EPSTEIN, TODD MATTHEW | — |
| Art Unit | Apps |
|---|---|
| 1652 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19041885 | COMPOSITE ENGINEERED BACTERIA AND METHOD FOR PRODUCING D-PSICOSE | PAK, YONG D | 1652 | §101§103§112DP | Non-Final OA | — | Pending | Jan 30, 2025 |
| 19041945 | ENZYME COMBINATION, GENETICALLY ENGINEERED BACTERIA, AND APPLICATION THEREOF IN PRODUCING D-PSICOSE | EPSTEIN, TODD MATTHEW | 1652 | §103§112 | Non-Final OA | — | Pending | Jan 30, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHenan Zhongda Hengyuan Biotechnology Stock Co. Ltd. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Yong D Pak has the most, with 1 of Henan Zhongda Hengyuan Biotechnology Stock Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
